3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
304
Stomach Neoplasms
34
Neoplasm Metastasis
24
Neoplasms
16
Colorectal Neoplasms
16
Breast Neoplasms, Male
16
HER2-positive Breast Cancer
11
Inflammatory Breast Neoplasms
10
Triple Negative Breast Neoplasms
9
Esophageal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
8
Brain Neoplasms
8
Rectal Neoplasms
7
Adenocarcinoma
7
Colonic Neoplasms
6
Urinary Bladder Neoplasms
5
Pathologic Complete Response
5
Biliary Tract Neoplasms
5
Urologic Neoplasms
4
Salivary Gland Neoplasms
4
Prostatic Neoplasms
4
Lung Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Ductal, Breast
4
Recurrence
3
Pancreatic Neoplasms
3
Neoplastic Cells, Circulating
3
Multiple Myeloma
3
Meningeal Neoplasms
3
HER2-positive Gastric Cancer
3
Interventions
Pemetrexed
5
Bevacizumab
5
osimertinib
3
aflutinib
3
Temozolomide
3
trastuzumab deruxtecan
2
Topotecan
2
Spinal Puncture
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
tucatinib
1
trioctyl phosphine oxide
1
pembrolizumab
1
nimotuzumab
1
merphos
1
lenvatinib
1
glutathione pegylated liposomal doxorubicin
1
epothilone B
1
envafolimab
1
camrelizumab
1
XL647
1
Trastuzumab
1
Transplantation, Autologous
1
Radiotherapy
1
Radiosurgery
1
Nivolumab
1
Mental Status and Dementia Tests
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Meningeal Carcinomatosis
×
Trastuzumab
×
Clear all
NCT05800275
2025-11-18
ETIC-LM
UNICANCER
Phase 2
Recruiting
30 enrolled